Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCI-024 + BCI-049 extension in MDD
NCT00731653Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Jul 2008
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of buspirone, melatonin in major depressive disorder (MDD), sponsored by Massachusetts General Hospital. Started Jul 2008; status: completed.
02
Drugs
buspironemelatonin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00731653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00731653.